Published in Br J Cancer on April 20, 2010
5-Chloro-2-hy-droxy-benzoic acid. Acta Crystallogr Sect E Struct Rep Online (2010) 0.99
PBOX-15, a novel microtubule targeting agent, induces apoptosis, upregulates death receptors, and potentiates TRAIL-mediated apoptosis in multiple myeloma cells. Br J Cancer (2010) 0.85
Involvement of AMP-activated protein kinase in mediating pyrrolo-1,5-benzoxazepine-induced apoptosis in neuroblastoma cells. Invest New Drugs (2016) 0.78
Y-632 inhibits heat shock protein 90 (Hsp90) function by disrupting the interaction between Hsp90 and Hsp70/Hsp90 organizing protein, and exerts antitumor activity in vitro and in vivo. Cancer Sci (2016) 0.76
The pyrrolo-1,5-benzoxazepine, PBOX-15, enhances TRAIL‑induced apoptosis by upregulation of DR5 and downregulation of core cell survival proteins in acute lymphoblastic leukaemia cells. Int J Oncol (2016) 0.76
The novel pyrrolo-1,5-benzoxazepine, PBOX-15, synergistically enhances the apoptotic efficacy of imatinib in gastrointestinal stromal tumours; suggested mechanism of action of PBOX-15. Invest New Drugs (2016) 0.76
Pre-clinical evaluation of a novel class of anti-cancer agents, the Pyrrolo-1, 5-benzoxazepines. J Cancer (2016) 0.75
Antitumor effect of pyrrolo-1,5-benzoxazepine-15 and its synergistic effect with Oxaliplatin and 5-FU in colorectal cancer cells. Cancer Biol Ther (2016) 0.75
Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell (2002) 13.03
The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood (2004) 6.92
Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat Rev Drug Discov (2002) 6.13
The molecular biology of chronic myeloid leukemia. Blood (2000) 5.22
Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clin Cancer Res (2003) 4.55
Analysis of apoptosis by propidium iodide staining and flow cytometry. Nat Protoc (2006) 4.43
Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood (2007) 4.15
Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol (2007) 3.37
MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation. Blood (2006) 2.50
Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib. Mol Cell Biol (2006) 2.28
Specific targeted therapy of chronic myelogenous leukemia with imatinib. Pharmacol Rev (2003) 2.02
Preexistence and evolution of imatinib mesylate-resistant clones in chronic myelogenous leukemia detected by a PNA-based PCR clamping technique. Ann Hematol (2003) 2.01
A mutation conferring resistance to imatinib at the time of diagnosis of chronic myelogenous leukemia. N Engl J Med (2003) 1.72
SGX393 inhibits the CML mutant Bcr-AblT315I and preempts in vitro resistance when combined with nilotinib or dasatinib. Proc Natl Acad Sci U S A (2008) 1.71
Therapeutic options against BCR-ABL1 T315I-positive chronic myelogenous leukemia. Clin Cancer Res (2008) 1.70
Efficacy of SCH66336, a farnesyl transferase inhibitor, in conjunction with imatinib against BCR-ABL-positive cells. Mol Cancer Ther (2003) 1.60
Histone deacetylase inhibitor NVP-LAQ824 has significant activity against myeloid leukemia cells in vitro and in vivo. Leukemia (2004) 1.54
Presence of the BCR-ABL mutation Glu255Lys prior to STI571 (imatinib) treatment in patients with Ph+ acute lymphoblastic leukemia. Blood (2003) 1.50
Flow cytometry CD45 gating for immunophenotyping of acute myeloid leukemia. Leukemia (1997) 1.36
Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr-Abl-expressing human leukemia cells. Blood (2006) 1.36
A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance. Proc Natl Acad Sci U S A (2005) 1.30
Part II: management of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol (2007) 1.24
Histone deacetylase inhibitors promote STI571-mediated apoptosis in STI571-sensitive and -resistant Bcr/Abl+ human myeloid leukemia cells. Cancer Res (2003) 1.20
A sequential blockade strategy for the design of combination therapies to overcome oncogene addiction in chronic myelogenous leukemia. Cancer Res (2006) 1.18
Chronic myelogenous leukemia. Hematology Am Soc Hematol Educ Program (2001) 1.16
The two major imatinib resistance mutations E255K and T315I enhance the activity of BCR/ABL fusion kinase. Biochem Biophys Res Commun (2004) 1.16
Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells. Clin Cancer Res (2006) 1.12
Intratumor injection of the Hsp90 inhibitor 17AAG decreases tumor growth and induces apoptosis in a prostate cancer xenograft model. J Urol (2007) 1.09
Pyrrolo-1,5-benzoxazepines induce apoptosis in chronic myelogenous leukemia (CML) cells by bypassing the apoptotic suppressor bcr-abl. J Pharmacol Exp Ther (2001) 1.04
Direct intra-tumoral injection of zinc-acetate halts tumor growth in a xenograft model of prostate cancer. J Exp Clin Cancer Res (2009) 0.99
Synergistic interactions between DMAG and mitogen-activated protein kinase kinase 1/2 inhibitors in Bcr/abl+ leukemia cells sensitive and resistant to imatinib mesylate. Clin Cancer Res (2006) 0.89
Prolactin antagonist-endostatin fusion protein as a targeted dual-functional therapeutic agent for breast cancer. Cancer Res (2003) 0.88
Novel microtubule-targeting agents, pyrrolo-1,5-benzoxazepines, induce apoptosis in multi-drug-resistant cancer cells. Cancer Chemother Pharmacol (2009) 0.86
Identification of tubulin as the molecular target of proapoptotic pyrrolo-1,5-benzoxazepines. Mol Pharmacol (2006) 0.86
STI-571 (imatinib mesylate) enhances the apoptotic efficacy of pyrrolo-1,5-benzoxazepine-6, a novel microtubule-targeting agent, in both STI-571-sensitive and -resistant Bcr-Abl-positive human chronic myeloid leukemia cells. J Pharmacol Exp Ther (2007) 0.85
Chronic myeloid leukemia therapy: focus on second-generation tyrosine kinase inhibitors. Cancer Control (2009) 0.82
The novel tubulin-targeting agent pyrrolo-1,5-benzoxazepine-15 induces apoptosis in poor prognostic subgroups of chronic lymphocytic leukemia. Cancer Res (2009) 0.82
Pyrrolo-1,5-benzoxazepines induce apoptosis in HL-60, Jurkat, and Hut-78 cells: a new class of apoptotic agents. J Pharmacol Exp Ther (2000) 0.81
Abl tyrosine kinase inhibitors for overriding Bcr-Abl/T315I: from the second to third generation. Expert Rev Anticancer Ther (2008) 0.81
Homoharringtonine for the treatment of chronic myelogenous leukemia. Expert Opin Pharmacother (2008) 0.80
Selective induction of apoptosis by the pyrrolo-1,5-benzoxazepine 7-[[dimethylcarbamoyl]oxy]-6-(2-naphthyl)pyrrolo-[2,1-d] (1,5)-benzoxazepine (PBOX-6) in Leukemia cells occurs via the c-Jun NH2-terminal kinase-dependent phosphorylation and inactivation of Bcl-2 and Bcl-XL. J Pharmacol Exp Ther (2004) 0.80
Pyrrolo-1,5-benzoxazepines: a new class of apoptotic agents. Biochem Soc Trans (2001) 0.78
The pyrrolo-1,5-benzoxazepine, PBOX-6, inhibits the growth of breast cancer cells in vitro independent of estrogen receptor status and inhibits breast tumour growth in vivo. Oncol Rep (2005) 0.78
Sequential treatment with flavopiridol synergistically enhances pyrrolo-1,5-benzoxazepine-induced apoptosis in human chronic myeloid leukaemia cells including those resistant to imatinib treatment. Biochem Pharmacol (2010) 0.78
The novel pyrrolo-1,5-benzoxazepine, PBOX-21, potentiates the apoptotic efficacy of STI571 (imatinib mesylate) in human chronic myeloid leukaemia cells. Biochem Pharmacol (2008) 0.77
A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med (2013) 6.67
Apoptosis signaling. Annu Rev Biochem (2000) 6.18
Bone marrow augmentation of donor-cell chimerism in kidney, liver, heart, and pancreas islet transplantation. Lancet (1994) 5.54
Hippocampal long-term potentiation is impaired in mice lacking brain-derived neurotrophic factor. Proc Natl Acad Sci U S A (1995) 5.25
Increased osteoclast development after estrogen loss: mediation by interleukin-6. Science (1992) 5.18
Ciliary neurotrophic factor prevents degeneration of motor neurons in mouse mutant progressive motor neuronopathy. Nature (1992) 3.39
Insulin synthesis in a clonal cell line of simian virus 40-transformed hamster pancreatic beta cells. Proc Natl Acad Sci U S A (1981) 2.96
Three-dimensional H-1 MR spectroscopic imaging of the in situ human prostate with high (0.24-0.7-cm3) spatial resolution. Radiology (1996) 2.95
Mobilization of a Drosophila transposon in the Caenorhabditis elegans germ line. Nature (2001) 2.55
Autosomal dominant retinitis pigmentosa (ADRP): localization of an ADRP gene to the long arm of chromosome 3. Genomics (1989) 2.52
High prevalence of thymic tissue in adults with human immunodeficiency virus-1 infection. J Clin Invest (1998) 2.47
17 beta-estradiol inhibits interleukin-6 production by bone marrow-derived stromal cells and osteoblasts in vitro: a potential mechanism for the antiosteoporotic effect of estrogens. J Clin Invest (1992) 2.43
Intracoronary thrombolysis in evolving myocardial infarction. Am Heart J (1981) 2.43
FK 506 in clinical kidney transplantation. Transplant Proc (1991) 2.29
Cytoplasmic inclusion bodies in Escherichia coli producing biosynthetic human insulin proteins. Science (1982) 2.21
Virus-mediated gene transfer into hippocampal CA1 region restores long-term potentiation in brain-derived neurotrophic factor mutant mice. Proc Natl Acad Sci U S A (1996) 2.10
Pneumothorax in the newborn. Neonatal Netw (1991) 2.03
BDNF controls dopamine D3 receptor expression and triggers behavioural sensitization. Nature (2001) 1.84
Molecular cloning, expression and regional distribution of rat ciliary neurotrophic factor. Nature (1990) 1.80
Loss of estrogen upregulates osteoblastogenesis in the murine bone marrow. Evidence for autonomy from factors released during bone resorption. J Clin Invest (1998) 1.73
Ventricular contraction abnormalities in dilated cardiomyopathy: effect of biventricular pacing to correct interventricular dyssynchrony. J Am Coll Cardiol (2000) 1.73
A single nucleotide polymorphism in the E-cadherin gene promoter alters transcriptional activities. Cancer Res (2000) 1.70
Biosynthesis of porphyrins and related macrocycles. Part 10. Vitamin B12: biochemical derivation of cobyrinic acid from uroporphyrinogen III. Studies with corresponding ring c methyl heptacarboxylic prophyrinogen, and proof of seven intact methyl transfers. J Chem Soc Perkin 1 (1977) 1.69
Mutation of the slow myosin heavy chain rod domain underlies hyaline body myopathy. Neurology (2004) 1.67
Chronic treatment with finasteride daily does not affect spermatogenesis or semen production in young men. J Urol (1999) 1.67
Stimulus control and generalization of point-loss punishment with humans. J Exp Anal Behav (2000) 1.61
Indications for and the significance of seminal vesicle irradiation during 3D conformal radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys (1994) 1.58
Obstructive response of human bladder to BPH vs. rabbit bladder response to partial outlet obstruction: a direct comparison. Neurourol Urodyn (2000) 1.58
Thrombin-induced platelet aggregation is mediated by a platelet plasma membrane-bound lectin. Science (1978) 1.55
Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. J Clin Invest (1994) 1.55
Two-dimensional echocardiographic phase analysis. Its potential for noninvasive localization of accessory pathways in patients with Wolff-Parkinson-White syndrome. Circulation (1992) 1.53
Low frequency epithelial cells in bone marrow aspirates from prostate carcinoma patients are cytogenetically aberrant. Cancer (1998) 1.52
Scintigraphic assessment of sympathetic innervation after transmural versus nontransmural myocardial infarction. J Am Coll Cardiol (1991) 1.52
Activated protein C inhibits lipopolysaccharide-induced nuclear translocation of nuclear factor kappaB (NF-kappaB) and tumour necrosis factor alpha (TNF-alpha) production in the THP-1 monocytic cell line. Br J Haematol (2000) 1.51
Murine monoclonal anti-DNA autoantibodies bind to endogenous bacteria. J Immunol (1985) 1.49
The serotonin transporter: a primary target for antidepressant drugs. J Psychopharmacol (1998) 1.46
Fibrinogen is the receptor for the endogenous lectin of human platelets. Nature (1981) 1.45
The prothrombin gene variant G20210A but not factor V leiden may be associated with veno-occlusive disease following BMT. Bone Marrow Transplant (1999) 1.43
A second DNA methyltransferase repair enzyme in Escherichia coli. Proc Natl Acad Sci U S A (1988) 1.42
Infection of donor lymphocytes with human T lymphotrophic virus type 1 (HTLV-I) following allogeneic bone marrow transplantation for HTLV-I positive adult T-cell leukaemia. Br J Haematol (1994) 1.41
Mineralization and metabolic response in serially passaged adult rat bone cells. Calcif Tissue Int (1980) 1.41
Testosterone metabolism in the rat ventral prostate. Biochem J (1968) 1.39
Mutations of the BCR-ABL-kinase domain occur in a minority of patients with stable complete cytogenetic response to imatinib. Leukemia (2007) 1.39
Novel symptomatology and changing epidemiology of domoic acid toxicosis in California sea lions (Zalophus californianus): an increasing risk to marine mammal health. Proc Biol Sci (2008) 1.38
Clinical application of pulse oximetry. Pediatr Nurs (1993) 1.38
Effects of long-term right ventricular apical pacing on left ventricular perfusion, innervation, function and histology. J Am Coll Cardiol (1994) 1.37
The Escherichia coli AlkB protein protects human cells against alkylation-induced toxicity. J Bacteriol (1994) 1.35
Reduced size of retinal ganglion cell axons and hypomyelination in mice lacking brain-derived neurotrophic factor. Mol Cell Neurosci (1997) 1.33
Oxygen dependent lactate utilization by Lactobacillus plantarum. Arch Microbiol (1985) 1.31
The role of bim, a proapoptotic BH3-only member of the Bcl-2 family in cell-death control. Ann N Y Acad Sci (2000) 1.31
Membrane cholesterol modulates serotonin transporter activity. Biochemistry (2001) 1.30
Hypoxia in prostate cancer: a powerful shield against tumour destruction? Cancer Treat Rev (2008) 1.30
Epidermal growth factor and transforming growth factor alpha bind differently to the epidermal growth factor receptor. Biochemistry (1989) 1.30
Cytokine manipulation of primitive human hematopoietic cell self-renewal. Proc Natl Acad Sci U S A (1997) 1.29
Blockade of JAK2-mediated extrinsic survival signals restores sensitivity of CML cells to ABL inhibitors. Leukemia (2011) 1.28
GABAergic stimulation regulates the phenotype of hippocampal interneurons through the regulation of brain-derived neurotrophic factor. Neuron (1996) 1.28
Plasma vitamin A in patients with bronchial carcinoma. Br J Cancer (1976) 1.27
Do parakeets exhibit derived stimulus control? Some thoughts on experimental control procedures. J Exp Anal Behav (1998) 1.24
Isolation, cultivation, and characterization of Borrelia burgdorferi from rodents and ticks in the Charleston area of South Carolina. J Clin Microbiol (2000) 1.19
Combined kidney/bone marrow transplantation--evidence of augmentation of chimerism. Transplantation (1995) 1.19
Glucose-induced alterations in nerve metabolism: current perspective on the pathogenesis of diabetic neuropathy and future directions for research and therapy. Diabetes Care (1985) 1.18
Ciliary neurotrophic factor. J Neurobiol (1994) 1.17
Characterization of BCR-ABL deletion mutants from patients with chronic myeloid leukemia. Leukemia (2008) 1.17
Metabolic syndrome, central obesity and insulin resistance are associated with adverse pathological features in postmenopausal breast cancer. Clin Oncol (R Coll Radiol) (2010) 1.17
The endogenous lectin of human platelets is an alpha-granule component. Blood (1981) 1.16
Tacrolimus: a potential new treatment for autoimmune chronic active hepatitis: results of an open-label preliminary trial. Am J Gastroenterol (1995) 1.16
Autosomal dominant retinitis pigmentosa: a new multi-allelic marker (D3S621) genetically linked to the disease locus (RP4). Hum Genet (1991) 1.16
Purification of porphobilinogen deaminase from Euglena gracilis and studies of its kinetics. Biochem J (1981) 1.15
Heterogeneity of erbB-2 gene amplification in bladder cancer. Cancer Res (1993) 1.14
Autosomal dominant retinitis pigmentosa: linkage to rhodopsin and evidence for genetic heterogeneity. Genomics (1990) 1.14
The tyrosine kinase inhibitor STI571, like interferon-alpha, preferentially reduces the capacity for amplification of granulocyte-macrophage progenitors from patients with chronic myeloid leukemia. Exp Hematol (2000) 1.14
The reception of androgens in the rat ventral prostate. Biochem J (1969) 1.12
Methylation of the E-cadherin gene promoter correlates with progression of prostate cancer. J Urol (2001) 1.12
Brain-derived neurotrophic factor modulates the development of the dopaminergic network in the rodent retina. J Neurosci (1998) 1.11
Relation of activity levels to body fat in infants 6 to 12 months of age. J Pediatr (1995) 1.11
Long-range changes in a protein antigen due to antigen-antibody interaction. Biochemistry (1992) 1.11
Scintigraphic assessment of MIBG uptake in globally denervated human and canine hearts--implications for clinical studies. J Nucl Med (1992) 1.10
Attention deficit/hyperactivity disorder (ADHD) symptoms and digit ratios in a college sample. Am J Hum Biol (2006) 1.09
Insecticide susceptibility of Aedes aegypti from Santo Domingo, Dominican Republic. J Am Mosq Control Assoc (1991) 1.08
Epidermal-growth-factor-receptor expression is associated with rapid tumor proliferation in bladder cancer. Int J Cancer (1994) 1.08
The influence of cyclosporin alone, or cyclosporin and methotrexate, on the incidence of mixed haematopoietic chimaerism following allogeneic sibling bone marrow transplantation for severe aplastic anaemia. Bone Marrow Transplant (2006) 1.08
Cryptic physiological trophic support of motoneurons by LIF revealed by double gene targeting of CNTF and LIF. Curr Biol (1996) 1.08
Stomatin, a MEC-2 like protein, is expressed by mammalian sensory neurons. Mol Cell Neurosci (1999) 1.07
Platelet plasma membrane lectin activity. Biochem Biophys Res Commun (1977) 1.07
Constraints on semantic priming in reading: a fixation time analysis. Mem Cognit (1986) 1.07
Activation of NF-kappa B and induction of vascular cell adhesion molecule-1 and intracellular adhesion molecule-1 expression in human glial cells by IL-1. Modulation by antioxidants. J Immunol (1994) 1.07
Characterization of protein C receptor expression in monocytes. Br J Haematol (2001) 1.06
Immunocytochemical demonstration of human proinsulin chimeric polypeptide within cytoplasmic inclusion bodies of Escherichia coli. Eur J Cell Biol (1983) 1.06
Wilms' tumor gene 1 (WT1) expression in childhood acute lymphoblastic leukemia: a wide range of WT1 expression levels, its impact on prognosis and minimal residual disease monitoring. Leukemia (2006) 1.06
Sexual transmission of human papillomaviruses in heterosexual and male homosexual couples, studied by DNA hybridisation. Genitourin Med (1988) 1.05
Peripheral-type benzodiazepine receptors. Gen Pharmacol (1997) 1.05
The thiamine status of patients with cancer as determined by the red cell transketolase activity. Int J Vitam Nutr Res (1974) 1.05
Scintigraphic assessment of regional cardiac adrenergic innervation. Circulation (1989) 1.05
Tacrolimus (FK 506), a treatment for primary sclerosing cholangitis: results of an open-label preliminary trial. Am J Gastroenterol (1995) 1.05
Deletion of Y-chromosome specific genes in human prostate cancer. J Urol (2000) 1.04
Pyrrolo-1,5-benzoxazepines induce apoptosis in chronic myelogenous leukemia (CML) cells by bypassing the apoptotic suppressor bcr-abl. J Pharmacol Exp Ther (2001) 1.04
Adult respiratory distress syndrome complicating severely uncontrolled diabetes mellitus: report of nine cases and a review of the literature. Diabetes Care (1987) 1.04